J&J, Medivir's hepatitis C drug simeprevir should be approved, FDA advisers say
This article was originally published in Scrip
Executive Summary
Johnson & Johnson’s hepatitis C drug simeprevir should be approved, a panel of US FDA advisers unanimously agreed.